1 Lebovitz HE, "Thiazolidinediones : the forgotten diabetes medications" 19 : 151-, 2019
2 Yki-Järvinen H, "Thiazolidinediones" 351 : 1106-1118, 2004
3 Akinmokun A, "The short insulin tolerance test for determination of insulin sensitivity : a comparison with the euglycaemic clamp" 9 : 432-437, 1992
4 Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial" 366 : 1279-1289, 2005
5 Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on sarcopenia in older people" 39 : 412-423, 2010
6 van Baar MJB, "SGLT2 inhibitors in combination therapy : from mechanisms to clinical considerations in type 2 diabetes management" 41 : 1543-1556, 2018
7 Nelinson DS, "SGLT2 inhibitors : a narrative review of efficacy and safety" 121 : 229-239, 2021
8 Kim SK, "Ratio of waist-to-calf circumference and carotid atherosclerosis in Korean patients with type 2 diabetes" 34 : 2067-2071, 2011
9 Jin SM, "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes : a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension" 17 : 599-602, 2015
10 Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes" 373 : 2117-2128, 2015
1 Lebovitz HE, "Thiazolidinediones : the forgotten diabetes medications" 19 : 151-, 2019
2 Yki-Järvinen H, "Thiazolidinediones" 351 : 1106-1118, 2004
3 Akinmokun A, "The short insulin tolerance test for determination of insulin sensitivity : a comparison with the euglycaemic clamp" 9 : 432-437, 1992
4 Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial" 366 : 1279-1289, 2005
5 Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on sarcopenia in older people" 39 : 412-423, 2010
6 van Baar MJB, "SGLT2 inhibitors in combination therapy : from mechanisms to clinical considerations in type 2 diabetes management" 41 : 1543-1556, 2018
7 Nelinson DS, "SGLT2 inhibitors : a narrative review of efficacy and safety" 121 : 229-239, 2021
8 Kim SK, "Ratio of waist-to-calf circumference and carotid atherosclerosis in Korean patients with type 2 diabetes" 34 : 2067-2071, 2011
9 Jin SM, "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes : a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension" 17 : 599-602, 2015
10 Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes" 373 : 2117-2128, 2015
11 Kovacs CS, "Empagliflozin improves glycaemic and weight control as addon therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes : a 24-week, randomized, placebo-controlled trial" 16 : 147-158, 2014
12 Kovacs CS, "Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus" 37 : 1773-1788.e1, 2015
13 Kim SG, "Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks : a multicenter, randomized, double-blind, parallel-group, placebo controlled trial" 9 : e92843-, 2014
14 Forst T, "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone" 16 : 467-477, 2014
15 홍아람 ; 구보경 ; 김상완 ; 이가희 ; 문민경, "Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice" 대한당뇨병학회 43 (43): 590-606, 2019
16 Rosenstock J, "Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy" 35 : 1473-1478, 2012
17 Rosenstock J, "Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy : a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin" 38 : 376-383, 2015
18 Blevins T, "Combination therapy for patients with uncontrolled type 2 diabetes mellitus : adding empagliflozin to pioglitazone or pioglitazone plus metformin" 14 : 789-793, 2015
19 DeFronzo RA, "Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin" 38 : 384-393, 2015
20 Kosiborod M, "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs : the CVD-REAL 2 study" 71 : 2628-2639, 2018
21 Mahaffey KW, "Canagliflozin for primary and secondary prevention of cardiovascular events : results from the CANVAS program(Canagliflozin Cardiovascular Assessment Study)" 137 : 323-334, 2018
22 Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes" 377 : 644-657, 2017
23 Levey AS, "A new equation to estimate glomerular filtration rate" 150 : 604-612, 2009
24 American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021" 44 (44): S111-S1124, 2021
25 Buse JB, "2019 update to : management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)" 43 : 487-493, 2020